Wockhardt (WOCKPHARMA) Fundamentals 2026 — P/E 142.0x, Revenue Analysis | SniperIQ
Wockhardt (WOCKPHARMA) is a India-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ₹30,285 Crore, trading at ₹1861.40 on the BSE. This SniperIQ fundamentals page covers Wockhardt's valuation (P/E 142.0x, P/B 6.1x), profitability (net margin 6.3%), revenue (₹3,373 Crore in FY2026), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Wockhardt's market cap?
Wockhardt (WOCKPHARMA) has a market capitalization of approximately ₹30,285 Crore, trading at ₹1861.40 on the BSE. Market cap moves with the live share price.
What is Wockhardt's P/E ratio?
Wockhardt's trailing twelve-month P/E ratio is 142.0x, with a price-to-book (P/B) of 6.1x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Wockhardt?
Wockhardt runs a net profit margin of 6.3%, a gross margin of 52.2%, and an operating margin of 19.6%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Wockhardt generate?
Wockhardt reported revenue of ₹3,373 Crore for fiscal year 2026, with net income of ₹213 Crore and earnings per share (EPS) of 13.12. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Wockhardt pay a dividend?
Wockhardt does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Wockhardt financially healthy?
Wockhardt carries a debt-to-equity ratio of 0.45x and a current ratio of 1.61x, with a market beta of 0.93. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Wockhardt a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Wockhardt (WOCKPHARMA) the key facts are: market cap ₹30,285 Crore, P/E 142.0x, revenue ₹3,373 Crore, 52-week range 1086.8-2420. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Wockhardt's full fundamentals live
Get Wockhardt's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.